Comparative Pharmacology
Head-to-head clinical analysis: ALOCRIL versus INTAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOCRIL versus INTAL.
ALOCRIL vs INTAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mast cell stabilizer that inhibits the release of inflammatory mediators (e.g., histamine, leukotrienes) from conjunctival mast cells. Also inhibits eosinophil chemotaxis and activation.
Mast cell stabilizer; inhibits degranulation of sensitized mast cells by blocking release of histamine and other inflammatory mediators.
2 drops in each eye four times daily; ophthalmic route.
2 inhalations (2 mg each) via nebulizer 4 times daily; or 20 mg via inhalation powder (Spinhaler) 4 times daily.
None Documented
None Documented
8.6 hours (terminal elimination half-life in healthy adults; may be prolonged in renal impairment, e.g., up to 18 hours in patients with severe renal dysfunction).
Terminal elimination half-life: 1.5-2 hours in plasma; clinical effect persists longer due to mast cell stabilization in airways.
Renal (primarily unchanged drug; approximately 50-60% excreted unchanged in urine within 48 hours). Biliary/fecal elimination accounts for <10%.
Primarily renal: unchanged drug (50-70%) and conjugated metabolites (20-30%); biliary/fecal: <5%.
Category C
Category C
Mast Cell Stabilizer
Mast Cell Stabilizer